13F Holdings
中文EN

IDXX IDEXX LABORATORIES INC /DE

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 874716 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.9%
TTM net income YoY15.1%
TTM EPS YoY17.7%
Revenue 3-yr CAGR9.1%
Net income 3-yr CAGR12.8%

Margins

Gross margin62.7%
Operating margin32.3%
Net margin25.4%
FCF margin28.0%
EBITDA margin35.7%

Returns

ROE68.9%
ROA33.3%
ROIC (approx.)61.4%
Asset turnover1.31x

Leverage & solvency

Liabilities / assets49.6%
Debt / equity0.20x
Current ratio1.19x
Interest coverage43.54x

Cash quality & payout

Operating cash flow / net income1.20x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.30B$3.90B$3.66B$3.37B$3.22B
Cost of revenue$1.64B$1.52B$1.47B$1.36B$1.33B
Gross profit$2.66B$2.38B$2.19B$2.00B$1.89B
R&D expense$251.21M$219.79M$190.95M$254.82M$161.01M
SG&A expense$404.79M$442.29M$335.82M$326.25M$309.66M
Operating income$1.36B$1.13B$1.10B$898.76M$932.03M
Interest expense$38.85M$31.20M$41.58M$39.86M$29.81M
Pretax income$1.32B$1.11B$1.06B$859.97M$902.65M
Income tax$264.73M$221.96M$216.13M$180.88M$157.81M
Net income$1.06B$887.87M$845.04M$679.09M$744.85M
EBITDA$1.51B$1.26B$1.21B$1.01B$1.04B
EPS (basic)13.1710.7710.178.128.74
EPS (diluted)13.0810.6710.068.038.60
Weighted avg. shares (diluted)81.03M83.25M83.98M84.60M86.57M
Banking
Provision for credit losses$8.43M$6.87M$5.55M$5.83M$1.48M
Balance sheet
Cash & equivalents$180.07M$288.27M$453.93M$112.55M$144.45M
Receivables$552.38M$473.57M$457.44M$400.62M$368.35M
Inventory$377.76M$381.88M$380.28M$367.82M$269.03M
Current assets$1.41B$1.40B$1.50B$1.10B$955.65M
PP&E, net$747.38M$713.12M$702.18M$649.47M$587.67M
Goodwill$414.00M$405.10M$366.00M$361.80M$359.35M
Intangibles$109.84M$111.68M$84.50M$97.67M$99.03M
Total assets$3.35B$3.29B$3.26B$2.75B$2.44B
Current liabilities$1.15B$1.07B$951.55M$1.24B$763.58M
Short-term debt$75.00M$167.79M$75.00M$74.98M$75.00M
Long-term debt$374.84M$449.79M$622.88M$694.39M$775.21M
Total debt$449.84M$617.57M$697.88M$769.37M$850.20M
Total liabilities$1.75B$1.70B$1.78B$2.14B$1.75B
Shareholders' equity$1.61B$1.60B$1.48B$608.74M$689.99M
Net debt$269.77M$329.31M$243.95M$656.82M$705.75M
Shares outstanding79.71M81.60M83.03M82.89M84.56M
Cash flow statement
Operating cash flow$1.18B$929.00M$906.51M$542.98M$755.55M
Capital expenditure$124.68M$120.92M$133.63M$148.84M$119.55M
Free cash flow$1.06B$808.08M$772.88M$394.15M$636.00M
Investing cash flow-$136.24M-$207.06M-$125.25M-$195.35M-$292.97M
Financing cash flow-$1.16B-$878.07M-$442.00M-$370.94M-$697.41M
Depreciation & amortization$145.18M$129.94M$114.91M$111.90M$104.60M
Stock-based compensation$60.01M$60.30M$59.74M$49.77M$37.76M
Share buybacks$1.22B$837.03M$71.92M$819.71M$746.78M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.